Novel pituitary ligands: Peroxisome proliferator activating receptor-γ

被引：26

作者：

Anthony P. Heaney

机构：

[1] Division of Endocrinology, Cedar-Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048

来源：

Pituitary | 2003年 / 6卷 / 3期

关键词：

Acromegaly; Apoptosis; Cushing's disease; Luteinising hormone; Pituitary neoplasms; PPAR-gamma; Prolactinoma;

D O I：

10.1023/B:PITU.0000011176.05771.46

中图分类号：

学科分类号：

摘要：

Pituitary tumors cause considerable morbidity due to local invasion, hypopituitarism, or hormone hypersecretion. In many cases, no suitable drug therapies are available, and surgical excision is currently the only effective treatment. We have recently demonstrated abundant expression of nuclear hormone receptor PPAR-γ in human pituitary tumors of different subtypes. PPAR-γ activators (thiazolidinediones) induced G0-G1 cell-cycle arrest and apoptosis in human, and murine corticotroph, somatolactotroph, and gonadotroph pituitary tumor cells, and suppressed in vitro hormone secretion. In vivo development and growth of murine corticotroph, somatolactotroph and gonadotroph tumors, generated by subcutaneous injection of ACTH-secreting AtT20, PRL- and GH-secreting GH3, and LH-secreting Lβ2, and α-T3 cells, was markedly suppressed in rosiglitazone treated mice, and plasma ACTH, and serum corticosterone, GH, PRL and LH levels were attenuated in all treated animals. PPAR-γ is an important novel molecular target in pituitary adenoma cells and as PPAR-γ ligands inhibit tumor cell growth and ACTH, GH, PRL and LH secretion in vitro and in vivo, thiazolidinediones are proposed as a novel oral medical management for pituitary tumors.

引用

页码：153 / 159

页数：6

共 79 条

[1]

Heaney A.P., Melmed S., Molecular pathogenesis of pituitary tumors, Oxford Textbook of Endocrinology, 2, pp. 109-120, (2002)

[2]

Sano K., Incidence of primary tumors (1969-1983), Neurol. Med. Chir., 37, SPEC. ISSUE, pp. 391-441, (1992)

[3]

Shimon I., Melmed S., Management of pituitary tumors, Ann. Intern. Med., 129, pp. 472-483, (1998)

[4]

Freda P.U., Wardlaw S.L., Primary medical therapy for acromegaly, J. Clin. Endocriol. Metab., 83, pp. 3031-3033, (1998)

[5]

Newman C.B., Melmed S., George A., Torigan D., Duhaney M., Snyder P., Et al., Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study, J. Clin. Endocrinol. Metab., 80, pp. 2768-2775, (1995)

[6]

Vance M.L., Harris A.G., Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of a multicenter acromegaly study group, Arch. Int. Med., 151, pp. 1573-1578, (1991)

[7]

Colao A., Ferone D., Marzullo P., Cappabianca P., Cirillo S., Boerlin V., Lancranjan I., Lombardi G., Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly, J. Clin. Endocrinol. Metab., 86, pp. 2779-2786, (2001)

[8]

Baldelli R., Colao A., Razzore P., Jaffrain-Rea M.L., Marzullo P., Ciccarelli E., Ferretti E., Ferone D., Gaia D., Camanni F., Lombardi G., Tamburrano G., Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg), J. Clin. Endocrinol. Metab., 85, pp. 4099-4103, (2000)

[9]

Freda P.U., Somatostatin analogs in acromegaly, J. Clin. Endocrinol. Metab., 87, pp. 3013-3018, (2002)

[10]

Melmed S., Casanueva F.F., Cavagini F., Chanson P., Frohman L., Glossman A., Ho K., Kleinberg D., Lamberts S., Laws E., Lombardi G., Vance M.L., Von Werder K., Wass J., Giustina A., Consensus: Guidelines for acromegaly management, J. Clin. Endocrinol. Metab., 87, pp. 4054-4058, (2001)

← 1 2 3 4 5 6 7 8 →